The 6 linked references in paper , , , , А. Калемберг А., К. Давтян В., Г. Симонян Ю., В. Шатахцян С. (2016) “CОВРЕМЕННЫЕ СТРАТЕГИИ ПРОФИЛАКТИКИ ТРОМБОЭМБОЛИЧЕСКИХ ОСЛОЖНЕНИЙ У ПАЦИЕНТОВ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ” / spz:neicon:aterotromboz:y:2016:i:2:p:7-13

  1. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. doi:10.1093/europace/ euv309. Published August 31, 2015.
  2. Reddy VY, Sievert H, Halperin J et al. Percutaneous Left Atrial Appendage Closure vs Warfarin for Atrial Fibrillation: A Randomized Clinical Trial.JAMA, 2014, 312(19): 1988-1998. doi:10.1001/jama.2014.15192.
  3. HRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. EuroIntervention 2014. 10-online publish-ahead-ofprint August 2014.
  4. Boersma LVA, Schmidt B еt al. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. European Heart Journal. doi:10.1093/eurheartj/ehv730.
  5. Holmes DR, Kar S, Price MJ et al. Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy: The PREVAIL Trial.J Am Coll Cardiol, 2014, 64(1): 1-12. doi:10.1016/j.jacc. 2014.04.029.
  6. Sandeep Panikker, Joanne Lord, et al. Outcomes and costs of left atrial appendage closure from randomized controlled trial and real world experience relative to oral anticoagulation. European Heart Journal, doi:10.1093/eurheartj/ehw048.